LONDON--(BUSINESS WIRE)--Technavio has announced their latest pipeline analysis report on the familial adenomatous polyposis market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat familial adenomatous polyposis.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.
THIS REPORT IS AVAILABLE AT A USD 1,000 DISCOUNT FOR A LIMITED TIME ONLY: VIEW MARKET SNAPSHOT BEFORE PURCHASING
Familial adenomatous polyposis: Market overview
Familial adenomatous polyposis (FAP) is an inherited disorder that causes extra tissue formation in the colon or large intestine and later forms cancer in the colon. FAP leads to the development of additional tissues, known as polyps, in the large intestine that can also form in the upper gastrointestinal tract, especially in the upper part of the small intestine. FAP has to be treated in the early stages, or else it becomes cancerous. The milder form of FAP is called attenuated familial adenomatous polyposis (AFAP) wherein the growth of polyps is slow.
According to a senior market research analyst at Technavio, “In order to develop a healthy pipeline, several companies are either forming planned exclusive licensing agreements or are acquiring companies. For instance, Tillotts Pharma entered into an exclusive agreement with Cancer Prevention Pharmaceuticals to help them in developing and commercializing the drug for the treatment of FAP in Europe, Japan, and North America.”
Familial adenomatous polyposis: Segmentation analysis
This pipeline analysis report segments the familial adenomatous polyposis market based on therapies employed (monotherapy and combination therapy), RoA (oral), therapeutic modality (small molecule and RNA), targets (beta-catenin, casein kinase 1 alpha, cyclooxygenase-2, and ornithine decarboxylase), MoA (beta-catenin inhibitor, casin kinase 1 alpha agonist, cyclooxygenase-2 inhibitor, immunosuppressant, and ornithine decarboxylase inhibitor), geographical segmentation (the US, the UK, Spain, Netherlands, Germany, Canada, and Belgium) and drugs under development (discovery, pre-clinical, phase I, phase I/II, and phase III). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
LOOKING FOR MORE INFORMATION ON THIS MARKET? REQUEST A FREE SAMPLE REPORT
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- RoA
- Therapeutic modality
- Geographical coverage
Recruitment Strategies
- Recruitment status
- Gender
- Age
Key Companies
- Type of players
- Company overview
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
